PERTH, Australia – The process to get innovative new drugs listed on Australia's Pharmaceutical Benefits Scheme (PBS) can be a long and arduous process, and pharma companies waiting to get innovative drugs listed will continue to face mounting pressure and lengthy price negotiations.
PERTH, Australia – New listings of higher-priced innovative drugs on Australia's government-subsidized Pharmaceutical Benefit Scheme (PBS) illustrate the government's commitment to list new innovative drugs, and pharma companies will see improved commercial opportunities in Australia, according to a recent BMI Research report.
PERTH, Australia – The process to get innovative new drugs listed on Australia's Pharmaceutical Benefits Scheme (PBS) can be a long and arduous process, and pharma companies waiting to get innovative drugs listed will continue to face mounting pressure and lengthy price negotiations.
PERTH, Australia – Australian biotech company Clinical Genomics Pty Ltd., of Sydney, will be able to dramatically expand the U.S. footprint of its liquid biopsy diagnostic to detect recurrent colon cancer following a new pact with the Netherlands-based Qiagen NV for its Paxgene blood collection system.
PERTH, Australia – Australian biotech company Clinical Genomics Pty Ltd., based in Sydney, will be able to dramatically expand the U.S. footprint of its liquid biopsy diagnostic to detect recurrent colon cancer following a new pact with the Netherlands-based Qiagen NV for its Paxgene blood collection system.
PERTH, Australia – A new technology spun out of Singapore's Agency for Science, Technology and Research (A*STAR) could change cancer treatment by building cell-based tumor avatars in the lab to test them against a multitude of drugs.
PERTH, Australia – A new technology spun out of Singapore's Agency for Science, Technology and Research (A*STAR) could change cancer treatment by building cell-based tumor avatars in the lab to test them against a multitude of drugs.
